Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion OyjORINY 93 5-Year Yield-on-Cost % is 2.56 as of Jul. 23, 2026, which is 39% below its 10-year median of 4.17. GuruFocus rates ORINY with a GF Score™ of 93/100 and a GF Value™ of $40.79 (Fairly Valued). The stock has 2 warning signs investors should review. Among 513 Drug Manufacturers companies, Orion Oyj ranks better than 52.24% on this metric.
Orion Oyj's yield on cost for the quarter that ended in Jun. 2026 was 2.56.
The historical rank and industry rank for Orion Oyj's 5-Year Yield-on-Cost % or its related term are showing as below:
ORINY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.83 Med: 4.17 Max: 9.44
Current: 2.56
During the past 13 years, Orion Oyj's highest Yield on Cost was 9.44. The lowest was 1.83. And the median was 4.17.
ORINY's 5-Year Yield-on-Cost % is ranked better than 52.24% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.27
vs ORINY: 2.56
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Orion Oyj 5-Year Yield-on-Cost % Related Terms
ORINY vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Orion Oyj's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Orion Oyj is calculated as
Orion Oyj (ORINY) has a 5-Year Yield-on-Cost % of 2.56 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Orion Oyj and its competitors. This is 39% below median its historical median of 4.17. Over the past decade, Orion Oyj's 5-Year Yield-on-Cost % has ranged from 1.83 to 9.44. According to the industry distribution chart, Orion Oyj ranks #245 out of 513 companies in the Drug Manufacturers industry, placing it in the top 47.8%.
Is Orion Oyj's 5-Year Yield-on-Cost % too high?
Orion Oyj's current 5-Year Yield-on-Cost % of 2.56 is 39% below median its 10-year median of 4.17. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 9.44. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.27. Orion Oyj's value of 2.56 is 12.8% above this industry median. Based on the distribution chart, Orion Oyj ranks #245 out of 513 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Oyj has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #245 out of 513 companies for 5-Year Yield-on-Cost %. This puts Orion Oyj in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.27. Orion Oyj's value of 2.56 is 12.8% above this benchmark. Historically, Orion Oyj's own 5-Year Yield-on-Cost % has ranged from 1.83 to 9.44 over the past decade. While the company's 10-year median is 4.17 vs. the industry median of 2.27, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current 5-Year Yield-on-Cost % of 2.56 is 12.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current 5-Year Yield-on-Cost % is 2.56, which is 39% below median its own 10-year median of 4.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Based on GuruFocus' analysis, Orion Oyj (ORINY) is currently considered Fairly Valued. The stock's GF Value™ is $40.79, compared to a current price of $43.02 — trading 5.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.56, which is 39% below median its 10-year median of 4.17 and 12.8% above the Drug Manufacturers industry median of 2.27. Orion Oyj's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Orion Oyj (ORINY), the current 5-Year Yield-on-Cost % is 2.56 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINY) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $43.02 is trading 5.5% above its estimated GF Value™ of $40.79.
GuruFocus considers Orion Oyj to be Fairly Valued.
Key valuation signals for ORINY:
5-Year Yield-on-Cost %: 2.56 (39% below median its 10-year median of 4.17)
GF Value™: $40.79 vs. price of $43.02 (5.5% above fair value)
Industry Position: 12.8% above the Drug Manufacturers median (#245 of 513)
No single metric tells the full story. See the ORINY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
93GF Score
Get the complete analysis for ORINY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINY has been successfully added to your 
